Dexcom beats The Street with Q4, FY18 results

This article was originally published here

 (NSDQ:DXCM) topped expectations on Wall Street this week with its fourth quarter and full-year financial results.

The San Diego, Calif.-based company posted a net loss of -$179.7 million, or -$2.03 per share, on sales of $338 million for the 3 months ended Dec. 31, for sales growth of 52.9% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom beats The Street with Q4, FY18 results appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply